Victoza (liraglutide)
Liraglutide for diabetes. Same drug as Saxenda at lower max dose.
Victoza is the FDA-approved liraglutide brand for type 2 diabetes. Approved in 2010, it was the first daily-injection GLP-1 medication. Generic liraglutide is now available at significantly lower cost.
Overview
Victoza is once-daily liraglutide 0.6-1.8 mg. It was approved by the FDA in 2010 for adults with type 2 diabetes, and in 2017 received an additional indication for cardiovascular risk reduction. It is approved down to age 10 for pediatric type 2 diabetes (the youngest age range of any GLP-1).
How Victoza Works
Same mechanism as Saxenda: GLP-1 receptor agonism. Appetite suppression, gastric emptying delay, glucose-dependent insulin, glucagon suppression.
Dosing & Schedule
Victoza titration: 0.6 mg daily → 1.2 mg → 1.8 mg (max for diabetes). Slower titration than Saxenda because target dose is lower.
Effectiveness — Trial Data
LEAD trials: A1c reduction 1.0-1.5% at 1.8 mg, with weight loss of about 2-3 kg. LEADER cardiovascular trial: 13% reduction in major cardiovascular events.
Side Effects
Nausea, diarrhea, vomiting, headache. Lower frequency than Saxenda due to lower dose.
Cost — How Much Victoza Costs in 2026
Victoza brand: $815-1,200/mo. Generic liraglutide ~$450/mo. Type 2 diabetes coverage is widespread, so insurance copays are typically reasonable.
Who Is Victoza For?
Adults and children 10+ with type 2 diabetes, including those with established cardiovascular disease.